Feasibility of Decentralised Response-Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease.
Diabetes Obes MetabJul 30, 2026 (epub)
Jelle M Beernink, Gozewijn D Laverman, Hiddo J L Heerspink
✦ AI-curated · Sources linked
In 30 seconds
This Phase IV clinical trial evaluated the feasibility of a decentralised response-guided approach for monitoring urinary albumin-to-creatinine ratio (UACR) in adults with type 2 diabetes and chronic kidney disease (CKD) receiving empagliflozin and finerenone. The study found that UACR decreased by 18.7% during empagliflozin monotherapy, with further reductions of 40.1% and 34.0% after adding or substituting finerenone, respectively.
Key findings
- All feasibility criteria were met, with urine sample delivery at 100%.
- UACR decreased by 18.7% during empagliflozin monotherapy.
- After finerenone addition, UACR was further reduced by 40.1%.
- No serious adverse events or hyperkalaemia were reported.
Why it matters
The study demonstrates that a decentralised approach to monitoring can effectively support individualized therapy optimization in patients with type 2 diabetes and CKD, potentially improving patient outcomes.